Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-204 in metastatic castration-resistant prostate cancer
NCT02344017Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Feb 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of ODM-204 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Orion Corporation. Primary endpoints: Incidence of adverse events at 6 months, Safety and tolerability assessed by vitals signs and 12-lead ECG at 6 months and 1 more. Started Feb 2015; status: completed.
02
Drugs
ODM-204
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02344017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02344017.